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A B S T R AC T 
Background: Previous research has shown that dysphagia 
and gastrointestinal problems occur frequently in carriers 
of the m.3243A>G mutation; however, the exact frequency 
and severity have not been determined. We hypothesise 
that adult carriers have an increased risk for malnutrition. 
Methods: In this observational study we evaluated the 
presence of gastrointestinal problems and dysphagia in 
92 carriers of the m.3243A>G mutation. The severity of 
the general disease involvement was classified using the 
Newcastle Mitochondrial Disease Adult Scale (NMDAS). 
Gastrointestinal involvement, dysphagia and the risk 
for malnutrition were scored using the Gastrointestinal 
Symptoms Questionnaire and the Malnutrition Universal 
Screening Tool. Gastrointestinal symptoms and 
anthropometrics were compared with healthy controls.
Results: Our results show that the height, weight and body 
mass index (BMI) of these carriers were lower than the 
national average (p < 0.05). Seventy-nine carriers (86%) 
suffered from at least one gastrointestinal symptom, 
mainly flatulence or hard stools. Both frequency and 
severity of symptoms were significantly increased 
compared with reference data of healthy Dutch adults. 
Of the carriers, 45% reported (mostly mild) dysphagia. 
Solid foods cause more problems than liquids. A negative 
correlation between BMI and heteroplasmy levels in 
urinary epithelial cells (UEC) was present (Spearman 
correlation coefficient = - 0.319, p = 0.003).
Conclusion: Dysphagia and gastrointestinal problems, 
especially constipation, are common symptoms in the 
total m.3243A>G carriers cohort and are not related 
to heteroplasmy levels in UEC or disease severity. The 
severity of gastrointestinal problems as well as overall 
disease severity is associated with an increased risk for 
malnutrition.
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I N T RODUC T I ON
Mitochondria and the m.3243A>G mutation
Mitochondrial diseases are the most prevalent inherited 
metabolic diseases, with an incidence of approximately 
1:5000 live births.1 Mitochondria are the cellular 
organelles responsible for oxidative phosphorylation, 
which produces energy in the form of adenosine 
triphosphate. This process is accomplished by the four 
complexes (complex I-IV) of the respiratory chain and 
F
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 ATP synthase. Mitochondrial dysfunction can 
result from mutations in either nuclear DNA (nDNA) or 
mitochondrial DNA (mtDNA). 
The acronym MELAS was first used by Pavlakis and 
Phillips2 to describe a group of patients with mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes. In 1990 the m.3243A>G mutation was found 
as the molecular basis of this disease.3,4 The mutation 
is located in the MT-TL1 gene and is the most common 
pathogenic mitochondrial mutation,5-7 commonly described 
as the MELAS mutation. The phenotype maternally 
inherited diabetes deafness (MIDD) is also caused by 
this same mutation and is much more frequent.8 Other 
phenotypic expressions of the m.3243A>G mutation 
include hypertrophic cardiomyopathy,9 retinal dystrophy,10 
focal segmental glomeruloslerosis,11 myoclonic epilepsy 
with ragged-red fibres12 and oligo-symptomatic variants 
of the acronym MELAS.13,14 The percentage of affected 
mitochondria per cell in a specific tissue is referred 
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to as heteroplasmy, and the level of heteroplasmy may 
vary widely between tissues of a single individual. This 
marked intra-individual and inter-individual variation 
in mitochondrial heteroplasmy partially explains why 
there is a wide spectrum of diseases and disease severity 
observed between family members that carry the same 
mitochondrial mutation. Previous studies have shown that 
urinary epithelial cells (UEC) are the best non-invasively 
available tissue to test the level of heteroplasmy of the 
m.3243A>G mutation.15,16
Gastrointestinal involvement in m.3243A>G carriers
Dysphagia and gastrointestinal problems occur 
frequently in mitochondrial patients, including patients 
carrying the m.3243A>G mutation.17-19 However, the 
exact frequency and severity of these symptoms have 
not been determined. In a population study of carriers 
of the m.3243A>G mutation, 61% of the subjects had 
gastro intestinal problems. These were, after hearing loss, 
the most frequently reported symptoms of the m.3243A>G 
mutation using the Newcastle Mitochondrial Disease Adult 
Scale (NMDAS).20 The NMDAS is, however, not a specific 
instrument to study gastrointestinal problems.
Previously, in a small cohort of MIDD patients, a high 
prevalence of constipation and/or diarrhoea (88%) was 
found.21 Severe gastrointestinal problems such as the 
pseudo-obstruction syndrome, surgery-requiring 
constipation and pancreatitis have been described in 
patients carrying the m.3243A>G mutation, although 
the incidence in these patients remains unclear.18,21 
Gastrointestinal problems are frequently reported in 
healthy controls as well,22 and so far studies comparing 
the frequency and severity of gastrointestinal problems in 
patients with a mitochondrial disease and healthy controls 
are lacking. 
Dysphagia in mitochondrial disease has been described 
in several studies which are hard to compare because of 
variations in definitions and study methods. In patients 
with the m.3243A>G mutation, incidences vary from 18% 
in a study using the NMDAS to score dysphagia to 38% 
in a study performed using a more specific approach.23,24 
Also, short stature and lower bodyweight are frequently 
described in mitochondrial disease. Patients with an 
MIDD phenotype have a lower body mass index (BMI, 
weight(kg)2/height(m)) compared with other diabetic 
patients.25,27 
For both dysphagia and gastrointestinal problems a relation 
with lower body weight and risk for malnutrition in 
patients with a mitochondrial disease has been suggested 
but never proven.18,21 The present study therefore focused 
on dysphagia and gastrointestinal problems in a cohort of 
carriers of the m.3243A>G mutation and identification of 
symptoms that lead to decreased BMI and increased risk 
for malnutrition. 
MAT E R I A L S  A N D  M E T HODS
Patients
At the Nijmegen Center for Mitochondrial Disorders 
(www.ncmd.nl) at Radboud university medical center, 114 
adult carriers of the m.3243A>G mutation participated 
in our cohort study.24 All participants received the 
questionnaire. This study was approved by the ethics 
committee of the Nijmegen-Arnhem region. Written 
informed consent according to the Helsinki agreement was 
obtained from all carriers.
General symptoms
All carriers were scored using the NMDAS.28 The NMDAS 
constitutes a validated method to monitor the clinical 
expression of mitochondrial disease and to follow up the 
course of disease over time. The NMDAS consists of the 
following four sections: 1) Current function, which gives 
insight into the general functioning of patients in the 
past four weeks, including swallowing; 2) System-specific 
involvement, which uses a clinical history supplemented 
by specific information to gain insight into the functioning 
of individual organ systems including gastrointestinal 
symptoms; 3) Current clinical assessment, i.e. a general 
and neurological clinical examination, which gives insight 
into the current functional status of the patient; 4) For 
quality of life, we used a Dutch translation of the SF-12v2 
quality of life test. 
Gastrointestinal symptoms evaluation
All participants received the Gastrointestinal Symptoms 
Questionnaire.29,30 This self-report questionnaire contains 
16 items regarding gastrointestinal involvement of disease 
for the past four weeks. Severity of the symptoms is 
scored on a 7-point Likert scale, where 0 indicates no 
symptoms and 6 indicates extreme symptoms. The 
final question of the questionnaire is a 50-point scale 
asking about the overall burden of the gastrointestinal 
symptoms. We added specific questions on dysphagia 
and frequency of stools. The validated Malnutrition 
Universal Screening Tool (MUST)31 was used to collect 
the self-reported anthropometric data and to screen for 
the risk for malnutrition. We compared the data to 
age-matched anthropometric data from the Dutch Central 
Bureau of Statistics (CBS) 2011 (n = 2034) and to a Dutch 
reference database from the Gastrointestinal Symptoms 
Questionnaire (n = 1616). Data collection for this reference 
database was done in 2006, participants who matched 
the general Dutch population were selected with CBS 
statistics.22
Mutation analysis
Heteroplasmy levels of the m3243A>G mutation 
were determined in UEC in all participants using 
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Pyrosequencing™ technology (Pyrosequencing, Uppsala, 
Sweden) as described earlier.11 The pyrosequence reaction 
of the m.3234A>G mutation had a precision of 1.5%, and 
the mutation was detected from a heteroplasmy level of 5%. 
The detection limit for the mutation was determined by 
serial dilution of a sample containing this mutation with 
wild type mtDNA.
Statistics
We used descriptive statistics to present the heteroplasmy 
levels in our patients. Means (±SD) are presented with their 
standard deviation. The independent samples T-test was 
used to calculate the significance of the different variables 
in relation to BMI and gastrointestinal symptoms. We 
corrected for multiple testing using the Bonferroni test. 
The Pearson correlation coefficient was used to evaluate 
the relationship between severity of gastro intestinal 
problems, and BMI. The Spearman correlation 
coefficient was used to evaluate the relationship between 
heteroplasmy in UEC, gastrointestinal problems, and BMI. 
We used the Pearson chi-square to compare BMI category 
for males and females and carriers with healthy controls.
R E SU LT S
General patient characteristics and anthropometrics
Data were collected from September to November 2011. 
From the 114 questionnaires that were sent out, 92 were 
returned (81% response rate). Of these 92 patients 68% 
(n = 63) were female. Mean age was 45 years (±14.3). In the 
Gastrointestinal Symptoms Questionnaire database mean 
age was 52.3 ± 17.2, 66% (n = 1067) were female.
Mean NMDAS score was 15.7 (±10.9), range 0-56, and 
average heteroplasmy level in UEC was 50% (range 5-98%). 
Thirty-eight patients (41%) were diagnosed with diabetes, 
of whom 22 (24%) used insulin. Hearing loss was reported 
by 59 patients (64%), 27 patients (29%) had a hearing aid. 
Six patients (6.5%) had severe neurological symptoms, of 
which five (5.4%) suffered from epilepsy and two (2.2%) 
had had stroke-like episodes in the past year.
Female carriers were 2.7 cm shorter (average 164.8 cm 
vs. 167.5 in healthy, p = 0.004) than healthy controls; 
in male carriers there was no significant difference 
between carriers and healthy controls (average 178.4 m 
vs. 180.9 in healthy controls, p = 0.099) (table 1). Male 
subjects weighed 8.2 kg less than controls (75.8 vs. 84 kg, 
p = 0.002) and females weighed 4.8 kg less (65.2 vs. 70 
kg, p = 0.005). 
Carriers had a significantly lower frequency of overweight 
(BMI > 25 kg/m2) or obesity (BMI> 30 kg/m2) (32%) 
compared with the average Dutch population (48%) 
(figure 1). They were significantly more frequently 
underweight (BMI < 20 kg/m2) than the average Dutch 
Table 1. Anthropometrics in male and female m.3243 
A>G carriers and healthy 40 to 50-year-old Dutch 
controls
m.3243A>G Healthy P value 
Height men (cm) 178.4 (± 6.9) 180.9 (± 7.9) 0.1
Height women (cm) 164.8 (± 8.3) 167.5 (± 7.1) 0.004* 
Weight men (kg) 75.8 (± 12.8) 84 (± 12.8) 0.002* 
Weight women (kg) 65.2 (± 17.7) 70 (± 12.8) 0.005* 
BMI men (kg/m2) 23.8 (± 3.6) 25.6 (± 5.4) 0.08 
BMI women (kg/m2) 23.9 (± 6) 24.6 (± 8.4) 0.5 
BMI category 0.00*
Overweight or obesity: 
BMI >25 n (%) men
11 (37) 588 (59.9)
Overweight or obesity: 
BMI >25 n (%) women
19 (30) 444 (42.2)
Healthy weight: BMI 
20-25 n (%) men
16 (53) 391 (39.9)
Healthy weight: BMI 
20-25 n (%) women
34 (54) 595 (56.5)
Low BMI < 20 n (%) 
men
3 (10) 2 (0.2)
Low BMI < 20 n (%) 
women
10 (16) 14 (1.3)
*p = <0.05. BMI = body mass index.
Figure 1. Body mass index in male and female 
m.3243A>G carriers and healthy Dutch controls
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population: 14 vs. 2%. Of the women with a NMDAS 
score above 20, 31% were underweight. Carriers with BMI 
< 20 kg/m2 had a significantly higher NMDAS (p = 0.01). 
A negative correlation between BMI and heteroplasmy 
levels in UEC was present in carriers of the m.3243A>G 
mutation (Spearman correlation coefficient = - 0.319, 
p = 0.003). Of the carriers, 19% (n = 17) had a MUST score 
of 1 or 2: average (12%) to high (7%) risk for malnutrition. 
In 14 carriers this score was based on their low BMI. Of 
the other three carriers with a risk for malnutrition, two 
had a healthy weight and one was overweight; their MUST 
scores were based on more than 5% loss of bodyweight in 
the last six months.
The majority of carriers (81%) had a MUST score of zero: 
no risk of malnutrition. Five percent of the m.3243A>G 
carriers used medical feeding supplements; no patients 
were dependent on tube feeding.
Gastrointestinal symptoms
In the four weeks prior to answering the questionnaire, 79 
carriers (86%) suffered from at least one gastrointestinal 
symptom. Nearly all gastrointestinal symptoms had a 
higher frequency and increased severity in carriers of the 
m.3243A>G mutation compared with the average Dutch 
population (figure 3). The most frequent problems were 
bloating, hard stools and flatulence. Nausea and diarrhoea 
and alternately solid or loose stools were also common but 
there was no significant difference to the controls for these 
symptoms. 
Hard stools or constipation were reported by 48% and 38% 
of the carriers, respectively, whereas controls only reported 
these symptoms in 22% and 14%, respectively (p < 0.001). 
Fourteen percent of the patients used laxatives and 44% 
had a stool frequency of less than once a day. 
Overall, 69% of the carriers of the m.3243A>G mutation 
reported one or more constipation-related symptom (use of 
laxatives, stool frequency of < 1 time a day, hard stools and/
or self-reported constipation).
Mean severity score of gastrointestinal problems was 10.7 
(± 11.9), range 0-50. Carriers with a BMI <20 (n = 13) 
(p = 0.028) and female carriers (p = 0.009) had a significantly 
higher severity score of gastrointestinal symptoms. 
Patients with postprandial fullness (p = 0.045) or vomiting 
(p = 0.048), had a significantly lower BMI compared 
with carriers without this specific symptom. Severity of 
gastro intestinal problems was not clinically relevantly related 
to BMI (correlation coefficient -0.152, p = 0.013) 
The gastrointestinal symptoms that were most frequently 
reported as severe (5, 6 or 7 on the 7-point Likert scale) 
were: hard stools (14%), constipation (11%), flatulence 
(11%) and bloating (10%). All of these symptoms were 
significantly more frequently scored as severe by carriers 
compared with controls. Also significantly more frequently 
scored as severe were regurgitation (8%), postprandial 
fullness (9%), belching (10%), dysphagia for solids (2%), 
incomplete stools (8%) and sticky stools (7%).
One patient in this cohort had a pancreatitis in the past, 
two patients needed surgery for severe constipation.
There was no correlation between heteroplasmy levels in 
UEC and gastrointestinal symptoms. Frequently reported 
symptoms in patients carrying the m.3243A>G mutation 
are myopathy and diabetes. The presence and severity 
of these symptoms had no significant relation to the 
gastro intestinal problems. 
Figure 2. Gastrointestinal symptoms in m.3243 A>G carriers and healthy Dutch controls 
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Dysphagia
In this study 21% of m.3243A>G carriers had trouble 
swallowing, as scored by the physician who performed 
the NMDAS. When we specifically asked for all sub-items 
of the NMDAS swallowing score in the questionnaire, 
this frequency was much higher: 45%. Using the 
Gastrointestinal Symptoms Questionnaire, dysphagia 
seems to be a frequent problem (33%), but the severity 
was not very high (figure 3). Liquids are less of a problem 
compared with solids; the difference with controls was 
significant both in the carriers who have trouble with 
liquids (p = 0.008) as with solids (p < 0.001). 
No significant differences in BMI were present in carriers 
reporting dysphagia compared with carriers without 
dysphagia. In six carriers with more severe complaints 
of trouble with swallowing liquids there was a significant 
difference in BMI: whereas carriers without trouble 
swallowing liquids had an average BMI of 24.1 (±5.5), 
carriers with such problems had an average BMI of 20.7 
(±3.1) (p = 0.046).
D I S CUS S I ON
As there currently is no cure for mitochondrial disease,32 
optimising nutrition and treating major symptoms such 
as constipation may be one of the few methods to improve 
quality of life. Because gastrointestinal symptoms are 
very common in these carriers as well as in the general 
population, and these often have a non-specific character, 
there may be a considerable risk for under-diagnosis of 
these possibly treatable problems. 
The present study shows for the first time in a robust 
cohort that dysphagia and gastrointestinal problems, 
and more specifically constipation, are very common in 
carriers of the m.3243A>G mutation. These symptoms 
are common in the total patient cohort and are not related 
to heteroplasmy levels in UEC, disease severity or the 
presence of diabetes. 
The severity of gastrointestinal problems as well as the 
overall disease severity and heteroplasmy levels in UEC 
are associated with a decreased BMI and an increased risk 
for the development of malnutrition. Strong points of this 
investigation include the high number of enrolled carriers 
with a homogeneous genetic background, despite the low 
incidence of this disease. Also, the high response rate 
renders these data highly relevant for the guidance and 
treatment of these carriers.
The high frequency of gastrointestinal problems has been 
previously described.17,18,21 We compared our cohort of 92 
carriers of the m.3243A>G mutation with a cohort of 1627 
healthy Dutch controls to identify those gastrointestinal 
problems that are specifically more frequent in carriers of 
the m.3243A>G mutation. Our study shows that motility 
problems of the bowel are probably the most frequent 
symptom: for instance, constipation was found in 69% 
of carriers of the m.3243A>G, i.e. much higher than in 
healthy controls. 
Patients presented with a range of underlying gastro- 
intestinal problems. Some were diagnosed with irritable 
bowel syndrome (IBS) prior to the mitochondrial 
diagnosis which does not seen surprising given the 
diversity of symptoms. Although nausea, diarrhoea and 
alternately solid or loose stools are common in this 
cohort, similar symptoms occur just as frequently in the 
control population, and do not seem to be specific for the 
m.3243A>G mutation, yet remain potentially treatable.
We show in this study that severe gastrointestinal 
symptoms increase the risk for malnutrition in carriers of 
the m.3243A>G mutation. Fourteen percent of carriers had 
a BMI of <20 kg/m2 and in more severely affected patients 
(NDMAS >20) even up to 31% had a BMI of <20 kg/m2. 
There was no relevant correlation between gastrointestinal 
problems and BMI, indicating that probably several other 
confounders such as depression or fatigue may contribute 
to the risk of malnutrition. Screening for malnutrition 
or gastrointestinal symptoms can lead to early detection, 
and hence early treatment of these problems. Since 
malnutrition has been related to secondary mitochondrial 
dysfunction and may worsen outcomes,33-35 as in other 
disease,36,37 this remains a major concern in these patients. 
Figure 3. Dysphagia in solids and liquids in m.3243 A>G 
carriers and healthy Dutch controls
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Dysphagia may well be more common than both doctors 
and patients realise. In a non-specific questionnaire for 
swallowing problems (as included in the NMDAS), a 
low prevalence of dysphagia was reported. For instance, 
in our previous study we reported an 18% incidence 
of dysphagia in a cohort of m.3243A>G carriers.24 In 
a partly overlapping cohort we now found that 45% of 
patients suffered from dysphagia using a more specific 
questionnaire based on the NMDAS. 
A patient-reported incidence of dysphagia of 33% was found 
using the Gastrointestinal Symptoms Questionnaire. 
These differences in reported incidences of dysphagia show 
that the method to diagnose dysphagia is instrumental 
when assessing its incidence and suggests that the NMDAS 
underestimates this problem. 
Dysphagia usually develops slowly and is not severe in 
most patients, and patients may therefore adapt their 
eating pattern sufficiently. This notion might also explain 
why no differences in BMI between patients with mild 
dysphagia and without dysphagia were found. As with 
other neuromuscular disorders, solid foods seem to cause 
more problems than liquids.38 Muscle weakness is the 
most likely cause for dysphagia in this patient group and 
demands a different treatment strategy than dysphagia 
from other causes.19,38 For example, in dysphagia due to 
cerebral damage, it is very common to prescribe thickened 
drinks which will aggravate dysphagia in mitochondrial 
patients and will take more energy to consume.
In this study we used low BMI as a marker for malnutrition, 
because it is an easily available variable suitable for 
comparison with healthy controls and for statistical analyses. 
BMI, however, is not a validated variable for malnutrition in 
neuromuscular disorders and it is known that patients with 
normal BMI could suffer from low fat-free mass which is 
also an important marker for malnutrition. In future studies 
we would like to recommend to use body composition as an 
additional marker.
In conclusion, gastrointestinal problems and dysphagia 
are common in carriers of the m.3243A>G mutation. The 
severity of the gastrointestinal problems as well as the 
overall disease severity is associated with an increased risk 
for the development of malnutrition. The common disease 
scores used to identify severity of disease in mitochondrial 
patients are insufficient to recognise these gastrointestinal 
symptoms. Healthcare professionals treating patients with the 
m.3243A>G mutation should be aware of this high prevalence 
and should therefore actively ask about gastrointestinal 
symptoms to ensure a timely treatment of these problems.
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